Renal denervation for treatment of ventricular arrhythmias

• Verfasst von: Ukena, Christian [VerfasserIn]
• Verfasst von: Scholz, Eberhard P. [VerfasserIn]
• Verfasst von: Thomas, Dierk [VerfasserIn]
• Titel: Renal denervation for treatment of ventricular arrhythmias
• Titelzusatz: data from an International Multicenter Registry
• Verf.angabe: Christian Ukena, Felix Mahfoud, Sebastian Ewen, Andreas Bollmann, Gerhard Hindricks, Boris A. Hoffmann, Dominik Linz, Dan Musat, Valerie Pavlicek, Eberhard Scholz, Dierk Thomas, Stephan Willems, Michael Böhm, Jonathan S. Steinberg
• Umfang: 7 S.
• Fussnoten: Gesehen am 29.11.2017
• Titel Quelle: Enthalten in: Clinical research in cardiology
• Jahr Quelle: 2016
• Band/Heft Quelle: 105(2016), 10, S. 873-879
• ISSN Quelle: 1861-0692
• DOI: doi:10.1007/s00392-016-1012-y
• Datenträger: Online-Ressource
• Sprache: eng
• K10plus-PPN: 1565824342

Abstract

IntroductionVentricular arrhythmias (VAs) in patients with chronic heart failure (CHF) are sometimes refractory to antiarrhythmic drugs and cardiac ablation. This study aimed to investigate catheter-based renal sympathetic denervation (RDN) as antiarrhythmic strategy in refractory VA.MethodsThese are the first data from a pooled analysis of 13 cases from five large international centers (age 59.2 ± 14.4 years, all male) with CHF (ejection fraction 25.8 ± 10.1 %, NYHA class 2.6 ± 1) presented with refractory VA who underwent RDN. Ventricular arrhythmias, ICD therapies, clinical status, and blood pressure (BP) were evaluated before and 1-12 months after RDN.ResultsWithin 4 weeks prior RDN, a median of 21 (interquartile range 10-30) ventricular tachycardia (VT) or fibrillation (VF) episodes occurred despite antiarrhythmic drugs and prior cardiac ablation. RDN was performed bilaterally with a total number of 12.5 ± 3.5 ablations and without peri-procedural complications. One and 3 months after RDN, VT/VF episodes were reduced to 2 (0-7) (p = 0.004) and 0 (p = 0.006), respectively. Four (31 %) and 11 (85 %) patients of these 13 patients were free from VA at 1 and 3 months. Although BP was low at baseline (116 ± 18/73 ± 13 mmHg), no significant changes of BP or NYHA class were observed after RDN. During follow-up, three patients died from non-rhythm-related causes.ConclusionsIn patients with CHF and refractory VA, RDN appears to be safe concerning peri-procedural complications and blood pressure changes, and is associated with a reduced arrhythmic burden.